MTX-325

An oral small molecule, also called MTX115325. It targets USP30, an enzyme that removes the tags used to mark damaged mitochondria for disposal. Blocking that enzyme is intended to help cells clear faulty mitochondria; this recycling process is called mitophagy. Fang et al.: USP30 inhibition in a Parkinson's disease mouse model (Animal context · Accessed 2026-09-30)

MTX-325 is an experimental oral compound targeting mitochondrial recycling, being developed for Parkinson’s disease. Longevity discussion treats it as a possible way to improve cellular housekeeping, but the available community material does not establish how taking it feels or whether healthy people benefit.

The comparison with Urolithin A has limits. The old longevity discussion groups MTX-325 with Urolithin A, MOTS-c and SS-31 because all attract mitochondrial-health interest. MTX-325 is a distinct enzyme inhibitor, not a stronger serving of Urolithin A or a peptide requiring reconstitution.

“Giga urolithin” is an analogy, not a potency measurement. The preserved longevity nickname suggests stronger mitochondrial recycling and brain reach. No linked original tweet or head-to-head result establishes that comparison. It should not imply a larger energy boost, better endurance or faster onset than Mitopure.

Source context — Fang et al.: USP30 inhibition in a Parkinson's disease mouse model: Mouse and cell research with Mission-affiliated authors. Brain drug concentration/target binding is not human bodily half-life, felt onset or benefit duration. Nature PDF and PMC browser tools were blocked; direct PMC HTML succeeded.

Protecting brain cells is the main hope. Kukreja’s social post asks whether better mitochondrial quality control can protect dopamine-producing neurons in Parkinson’s disease. This is a research question; it does not report improved movement, mood or concentration after taking MTX-325. Gagan Kukreja: Crystal structure of USP30 inhibitor, a new hope for Parkinson's (Community guide · Accessed 2026-09-30)

Longevity interest extends beyond the disease program. Phil Newman frames mitophagy as relevant to ageing, while promoting Longevity.Technology coverage. That broader appeal explains interest in energy and cellular maintenance, but his article offers no healthy-user outcomes. Phil Newman: When the clean-up crew falters, mitophagy and Parkinson's (Community opinion · Accessed 2026-09-30)

No reliable first-dose or first-week feel timeline. The old notes contain pipeline expectations rather than direct experience. Feeling more alert, having less brain fog or noticing nothing after Urolithin A cannot be relabeled as an MTX-325 response.

Source context — Gagan Kukreja: Crystal structure of USP30 inhibitor, a new hope for Parkinson's: User-created scientific commentary, not self-use. Its linked structural study was not inspected and is not assumed to be an MTX325 clinical result. Relative timestamp retained without invented date.

Source context — Phil Newman: When the clean-up crew falters, mitophagy and Parkinson's: Longevity-media promotion, not independent effectiveness evidence or a direct experience. Funding, trial and early-safety assertions derive from sponsor news and share its origin allowance; only the author's ageing interpretation is used here.

No substantiated community oral dose was found. The preserved notes provide no self-use milligrams, frequency, daily total or verified formulation. Fresh accessible social commentary supplies none either. Trial capsule strengths are separate context below, not a biohacker amount.

Urolithin A’s 500–1,000 mg numbers do not transfer. Those amounts appear in the old comparison with Urolithin A, not as MTX-325 use reports. SS-31 quantities likewise concern a different compound and route; neither comparison creates an MTX-325 dose band.

Phase 1: volunteer parts complete; Parkinson’s part in progress. The September 2026 registry posts no results. It lists 1.5–100 mg active oral capsule strengths across Parts 1–4 and 20 mg capsules for PET and Parkinson’s parts, without daily totals here. Its 50 mg placebo is not active drug; 28-day safety follow-up is not 28 days of dosing. ClinicalTrials.gov NCT07630545 study record (Official context · Accessed 2026-09-30)

Source context — ClinicalTrials.gov NCT07630545 study record: Registered design, capsule strengths and exclusion criteria, not outcome results. Strengths do not state per-administration or daily totals. Registry screening restrictions do not establish proven interactions or human adverse-event rates.

No reliable first-dose or first-week feel timeline. The old notes contain pipeline expectations rather than direct experience. Feeling more alert, having less brain fog or noticing nothing after Urolithin A cannot be relabeled as an MTX-325 response.

No documented benefit window or after-stopping timeline. The community record does not establish hours of energy, lasting neurological improvement or withdrawal. Its mitochondrial-maintenance framing is not evidence that an effect lasts all day, accumulates over weeks or continues after stopping.

No supported human half-life estimate in the community record. There is no traceable numerical estimate in the preserved discussion. Half-life means the time for the measured amount in the body to fall by half; a recycling mechanism or another compound’s daily schedule cannot supply it.

Mouse measurements are not human timing. The paper reports roughly 98% oral bioavailability, an unbound brain-to-plasma concentration ratio near 0.4 and about eight hours of 50% USP30 binding in mice. Neuron protection occurred in a mouse Parkinson’s model; none measures a human feel curve. Fang et al.: USP30 inhibition in a Parkinson's disease mouse model (Animal context · Accessed 2026-09-30)

Source context — Fang et al.: USP30 inhibition in a Parkinson's disease mouse model: Mouse and cell research with Mission-affiliated authors. Brain drug concentration/target binding is not human bodily half-life, felt onset or benefit duration. Nature PDF and PMC browser tools were blocked; direct PMC HTML succeeded.

No established community course or break pattern. The old stack wishlists are not dated treatment logs. There is no supported number of weeks on, weeks off or repeat interval; plans for chronic Parkinson’s treatment do not establish a longevity cycle.

Phase 1: volunteer parts complete; Parkinson’s part in progress. The September 2026 registry posts no results. It lists 1.5–100 mg active oral capsule strengths across Parts 1–4 and 20 mg capsules for PET and Parkinson’s parts, without daily totals here. Its 50 mg placebo is not active drug; 28-day safety follow-up is not 28 days of dosing. ClinicalTrials.gov NCT07630545 study record (Official context · Accessed 2026-09-30)

Source context — ClinicalTrials.gov NCT07630545 study record: Registered design, capsule strengths and exclusion criteria, not outcome results. Strengths do not state per-administration or daily totals. Registry screening restrictions do not establish proven interactions or human adverse-event rates.

A mitochondrial wishlist is not a tested combination. The old notes place MTX-325 near Urolithin A, NMN and MOTS-c, and discuss SS-31 comparisons. They describe related interests, without direct combination outcomes, component ratios or evidence that overlapping mitochondrial targets improve results.

A familiar compound name does not verify a product. The original discussion flags powders and capsules carrying MTX-325 or MTX115325 names as identity risks. A claimed mitochondrial stack could involve an unverified material, and changing several agents together makes any apparent response difficult to attribute.

Human safety remains incompletely described publicly. No trial results are posted. The protocol excludes pregnancy and breastfeeding and restricts several medicines, including venlafaxine and certain Parkinson’s drugs, plus NMN and nicotinamide riboside. Screening rules do not prove an interaction; long-term use outside the trial remains uncertain. ClinicalTrials.gov NCT07630545 study record (Official context · Accessed 2026-09-30)

Mouse measurements are not human timing. The paper reports roughly 98% oral bioavailability, an unbound brain-to-plasma concentration ratio near 0.4 and about eight hours of 50% USP30 binding in mice. Neuron protection occurred in a mouse Parkinson’s model; none measures a human feel curve. Fang et al.: USP30 inhibition in a Parkinson's disease mouse model (Animal context · Accessed 2026-09-30)

Source context — ClinicalTrials.gov NCT07630545 study record: Registered design, capsule strengths and exclusion criteria, not outcome results. Strengths do not state per-administration or daily totals. Registry screening restrictions do not establish proven interactions or human adverse-event rates.

Source context — Fang et al.: USP30 inhibition in a Parkinson's disease mouse model: Mouse and cell research with Mission-affiliated authors. Brain drug concentration/target binding is not human bodily half-life, felt onset or benefit duration. Nature PDF and PMC browser tools were blocked; direct PMC HTML succeeded.